Core Viewpoint - The surge in A-share and Hong Kong stock prices of innovative drug companies is driven by potential business development (BD) expectations, particularly for those seen as acquisition targets by multinational pharmaceutical companies [2][3] Group 1: Business Development Trends - Pfizer's recent $7.3 billion acquisition of Metsera signals a significant return to the weight-loss drug market, impacting domestic stock prices of related companies [2] - Global pharmaceutical transactions have increased from 358 in 2015 to 743 in 2024, with a compound annual growth rate of 8%, while China's transactions surged from 55 to 213, with total values rising from $3.1 billion to $57.1 billion [3] - Major Chinese companies like 3SBio, CSPC, and Hengrui have secured BD deals exceeding $5 billion this year, with Hengrui's $12.5 billion agreement with GSK setting a record for Chinese innovative drug exports [3] Group 2: Market Sentiment and Investor Behavior - Investors are becoming more discerning, focusing on the specifics of BD deals, such as upfront payment ratios and the long-term capabilities of partners, rather than merely the announcement of negotiations [4] - There is a growing concern that many top buyers have already completed their acquisitions, leading to potential valuation declines and tougher negotiations for remaining assets [4][5] - Past instances show that underwhelming BD deals can lead to significant stock price declines, as seen with Rongchang Bio and Hengrui [5] Group 3: Future Opportunities and Market Dynamics - Despite concerns about a potential slowdown in BD activity, industry leaders assert that opportunities continue to emerge, particularly as multinational companies adjust their R&D strategies every 5 to 10 years [7] - The demand for innovative assets remains strong, with a shift towards ADCs and bispecific antibodies, indicating a recognition of Chinese companies' R&D capabilities [8][9] - The trend of multinational companies seeking earlier-stage projects reflects a strategic shift towards building comprehensive product portfolios, as seen in Pfizer's acquisition of Metsera, which enhances its offerings in the GLP-1 space [9]

Investment Rating - The report maintains a "Buy" rating for several companies in the pharmaceutical sector, indicating an expectation of total returns exceeding the relevant industry over the next 12 months [4]. Core Insights - The recent announcement by President Trump regarding a 100% tariff on imported branded and patented drugs is expected to have a limited impact on China's innovative drug industry, as most Chinese companies either have production facilities in the U.S. or utilize local contract manufacturing organizations (CMOs) [3]. - The report suggests that investors should strategically position themselves in the innovative drug supply chain during market fluctuations, with several catalysts expected in Q4 2025, including the ESMO conference and upcoming healthcare negotiations [3]. - Long-term investment opportunities are highlighted in specific segments such as innovative drugs and CXO services, with recommendations for companies like Sanofi, Legend Biotech, and WuXi AppTec [3]. Summary by Sections Section: Impact of Tariffs - The 100% tariff on imported drugs is not expected to significantly affect Chinese innovative drug companies, as they have limited direct exports to the U.S. and often rely on local production [3]. - CXO companies primarily export raw materials and biological drugs, which are not impacted by the new tariffs, indicating a controlled overall impact on the Chinese pharmaceutical supply chain [3]. Section: Investment Recommendations - The report recommends focusing on companies with rich short-term catalysts, such as Kangfang Biotech and Rongchang Biotech, ahead of significant data releases and healthcare negotiations [3]. - Specific companies are highlighted for their growth potential, including Sanofi and Legend Biotech, which are considered undervalued with clear long-term growth logic [3]. Section: Company Ratings - A list of companies with their respective ratings and target prices is provided, showing a generally positive outlook for the majority of the companies covered [4]. - Notable companies with "Buy" ratings include Sanofi (target price of 35.00), Legend Biotech (target price of 74.00), and WuXi AppTec (target price of 70.00) [4].

Core Insights - The report highlights the acceleration of adjustments in medical insurance and commercial insurance directories, suggesting a strategic approach to invest in undervalued quality stocks during market corrections [1][2] - The innovation drug sector is expected to benefit from a gradually forming insurance guarantee model, which may alleviate challenges related to hospital admissions and reimbursement payments [2] Market Review - The Hang Seng Healthcare Index fell by 1.4% this week, underperforming the broader market, while sectors such as internet medicine, CXO, and traditional Chinese medicine showed relatively better performance [1] - Domestic institutional investors maintained stable holdings through the Hong Kong Stock Connect, while foreign investors slightly reduced their positions since mid-year, although both continue to increase their investments in innovative pharmaceutical companies [1] Investment Recommendations - Focus on companies with significant data releases at the upcoming ESMO conference, such as Kangfang Biologics, Kelun-Biotech, and Rongchang Biologics [2] - Suggested investment strategies include gradually positioning in the innovative drug sector during market pullbacks, with specific recommendations for: 1) Innovative drugs: Companies like 3SBio and Eucure Biopharma have rich short-term catalysts and their valuations do not yet reflect the core value of major products [2] 2) CXO: Leaders in this segment are expected to benefit from high downstream demand and improving financing conditions, such as WuXi AppTec [2]

Core Viewpoint - The Hong Kong stock market has experienced significant volatility over the past year, with the Hang Seng Index rising from approximately 17,000 points to over 27,000 points, marking a new high since 2022, driven by sectors such as AI, innovative pharmaceuticals, and new consumption [1][4][10]. Market Performance - The Hang Seng Index closed at 26,159 points, down 0.7%, while the Hang Seng Tech Index closed at 6,167 points, down 1.45% as of September 23 [1]. - The market has shown a "first strong, then slow, and then rebound" trend throughout the year, with the Hang Seng Index outperforming A-shares in the first half but lagging behind in July and August [6][10]. Sector Analysis - The technology sector, particularly in AI and innovative pharmaceuticals, has seen substantial gains, with stocks like SMIC rising over 120% and Alibaba increasing by over 90% [7]. - The innovative pharmaceutical sector has also gained traction, with companies like Innovent Biologics and BeiGene making significant international partnerships [7][11]. Market Dynamics - The Hong Kong stock market has seen a surge in liquidity, with average daily trading volume reaching 240.2 billion HKD in the first half of the year, a 118% increase year-on-year [4]. - The number of IPOs has increased significantly, with 51 IPOs raising 128 billion HKD in the first seven months of the year, surpassing the total for the previous year [9]. Future Outlook - Analysts remain optimistic about the future of the Hong Kong stock market, citing the potential for continued valuation recovery in sectors like technology and non-essential consumption [10][14]. - The market is expected to experience further upward movement, driven by structural industry recovery and the ongoing liquidity cycle [13][14].

Core Viewpoint - The Hong Kong stock market has experienced significant volatility over the past year, with the Hang Seng Index rising from around 17,000 points to over 27,000 points, marking a new high since 2022, driven by strong performance in sectors like AI, innovative pharmaceuticals, and new consumption [1][2][12] Market Performance - The Hang Seng Index reached a peak of 27,000 points in September 2024, following a series of financial policy announcements and a surprise rate cut by the Federal Reserve [2] - The Hang Seng Technology Index also showed strong performance, climbing from approximately 3,500 points to 6,461 points during the same period [2] - Recent market trends indicate a slight pullback, with the Hang Seng Index closing at 26,159 points, down 0.7%, and the Hang Seng Technology Index at 6,167 points, down 1.45% [1] Sector Analysis - The market has seen a structural shift with active rotation among sectors, including AI, new consumption, and innovative pharmaceuticals, leading to significant stock price increases for major players like Semiconductor Manufacturing International Corporation and Alibaba [7][10] - The innovative pharmaceutical sector has also gained traction, with companies like Innovent Biologics and BeiGene entering substantial partnerships, contributing to a rise in the Hang Seng Innovative Pharmaceutical Index by over 100% [7] Investment Trends - Over the past year, 543 stocks have doubled in price, with notable performers in consumer discretionary, healthcare, and financial sectors, including companies like Genscript Biotech and Zai Lab [9] - The Hong Kong IPO market remains robust, with 51 IPOs raising HKD 128 billion in the first seven months of the year, surpassing the total for the previous year [10] Liquidity and Capital Flow - The liquidity situation in the Hong Kong market has improved significantly, with average daily trading volume increasing by 118% year-on-year to HKD 2,402 billion [2][11] - Southbound capital inflow has been driven by domestic investors seeking stable returns and growth opportunities in Hong Kong, particularly in dividend-paying and growth sectors [11] Future Outlook - Analysts remain optimistic about the future of the Hong Kong stock market, anticipating continued valuation recovery in sectors like technology and new consumption, despite potential short-term lag due to A-share market dynamics [12][13] - The current market cycle is viewed as being in its mid-stage, with liquidity and valuation cycles leading the way, while the earnings cycle is just beginning [12]

Investment Rating - The report maintains an investment rating of "Outperform the Market" [5] Core Insights - The new drug sector has shown significant movements, with notable increases in stock prices for companies such as Kintor Pharmaceutical, which recently went public in Hong Kong, focusing on unmet clinical needs in oncology and immunology [2][3][21] - The KRAS G12D inhibitor GFH375 from Kintor Pharmaceutical has demonstrated promising clinical data in treating pancreatic cancer and non-small cell lung cancer (NSCLC), with an overall response rate (ORR) of 52% in pancreatic cancer and 68.8% in NSCLC [21][24] Summary by Sections Weekly New Drug Market Review - From September 15 to September 21, 2025, the top five gainers in the new drug sector included Kintor Pharmaceutical (+19.64%), Boan Biotechnology (+8.89%), and others, while the top five losers included Sanofi Pharmaceuticals (-17.16%) and others [1][13] Recommended Stocks to Watch - The report suggests focusing on several potential catalysts in the sector, including academic conferences and insurance negotiations. Key companies to watch include: 1. Differentiated GLP-1 assets: Zai Lab, EQRx, and others 2. Upgraded PD-1 products: CanSino Biologics and others 3. Companies likely to benefit from insurance negotiations: Hengrui Medicine, Kanghong Pharmaceutical, and others [2][17] New Drug Approval and Acceptance - This week, eight new drug applications were approved, and twelve new drug applications were accepted in China [3][25] Clinical Application Approvals - A total of 48 new drug clinical applications were approved, with 32 applications accepted this week [7][29]

Core Insights - The Chinese innovative pharmaceutical industry is experiencing significant growth as companies expand overseas through various strategies such as licensing, establishing overseas bases, and forming new companies [1][10] - A notable challenge faced by Chinese pharmaceutical companies is the shortage of talent, particularly when transitioning to international multi-center clinical trials [1][9] Group 1: Market Expansion - By 2025, Chinese innovative pharmaceutical companies are expected to maintain their momentum in international markets [1] - Over 40% of business development deals with upfront payments exceeding $50 million are now attributed to Chinese biotech firms, a significant increase from less than 5% four years ago [3] - The historical shift in global pricing power for Chinese innovative drugs reflects a transition from weakness to strength [3] Group 2: Case Studies - The case of Hutchison China MediTech illustrates the difficulties faced during global expansion, highlighting the need for collaboration with established pharmaceutical companies to navigate complex global operations [4] - The approval of the drug fruquintinib in the U.S. in late 2023, after a partnership with Takeda Pharmaceuticals, underscores the importance of strategic alliances in overcoming initial setbacks [4] Group 3: ADC Development - Antibody-drug conjugates (ADCs) have emerged as a key area for Chinese innovative drug development, with companies like WuXi AppTec and Kelun-Biotech securing significant deals with international firms [4] - The combination of chemical advantages and innovative approaches in ADC development positions Chinese companies favorably in the global market [4] Group 4: Talent Acquisition and Challenges - Talent shortages remain a critical challenge for Chinese pharmaceutical companies as they expand internationally, necessitating a focus on both recruitment and training [9] - WuXi AppTec's establishment of its first overseas factory in Singapore reflects a strategic choice based on execution, management, and government support [8] - The company emphasizes the importance of local talent availability and has implemented a strategy of combining local hiring with the relocation of domestic employees to build a balanced workforce [8][9] Group 5: Future Outlook - The next few years are expected to see an increase in the number of ADCs launched in China, with companies advised to align closely with the needs and development directions of multinational corporations [5] - The evolution of Chinese pharmaceutical companies into the "outbound 2.0 era" signifies a shift towards deeper integration into the global market and competition with top multinational firms [10]

Investment Rating - The report maintains an investment rating of "Outperform the Market - A" [6] Core Insights - The report highlights the promising clinical data of BaiLi Tianheng's EGFR/HER3 dual antibody ADC, iza-bren, for treating EGFR mutation lung cancer, which shows potential for further clinical advancement [2][3][20][21][23] Summary by Sections Weekly New Drug Market Review - From September 8 to September 14, 2025, the top five gainers in the new drug sector were: - Saintno Pharmaceutical (+32.00%) - Junshengtai (+23.73%) - Canaan Bio (+20.43%) - Rongchang Bio (+16.52%) - Hengrui Medicine (+11.91%) - The top five losers were: - Basestone Pharmaceuticals (-18.90%) - Laika Pharmaceuticals (-18.12%) - Gilead Sciences (-16.93%) - Maiwei Bio (-14.41%) - Yifang Bio (-12.46%) [1][15] Recommended Stocks to Watch - The report suggests focusing on several potential catalysts in the sector, including academic conferences, business development realizations, and insurance negotiations. Key stocks to watch include: 1. Potential overseas licensed MNC heavyweights: - Differentiated GLP-1 assets: Zhongsheng Pharmaceutical, Gilead Sciences, Borui Pharmaceutical, Kangyuan Pharmaceutical - Upgraded PD-1 products: Kangfang Bio and other PD-1/VEGF assets, Innovent Biologics - Breakthroughs in autoimmune fields: Yifang Bio, China Antibody - Innovative target ADCs: Fuhong Hanlin, Shiyao Group 2. MNC-certified products with high overseas volume certainty: - Upgraded PD-1 products: Sanofi Pharmaceutical - GLP-1 assets: Lianbang Pharmaceutical - ADC assets: Kelong Botai, BaiLi Tianheng 3. Products likely to benefit from insurance negotiations and innovative drug directories [2][20] New Drug Industry Focus Analysis - At the recent 2025 World Lung Cancer Conference (WCLC), BaiLi Tianheng presented results from two studies on its EGFR×HER3 dual antibody ADC, iza-bren, showing excellent clinical data in both first-line and second-line treatments for advanced or metastatic EGFR mutation NSCLC. The results indicate a promising future for its application in relevant indications [2][20][21] New Drug Approval and Acceptance Status - No new drug or new indication applications were approved this week, but seven new drug or new indication applications were accepted [3][25] Clinical Application Approval and Acceptance Status - This week, 41 new drug clinical applications were approved, and 46 new drug clinical applications were accepted [9][28]

Summary of Conference Call Records Industry Overview - The focus is on the **Chinese innovative pharmaceutical industry** and its strategies for 2025, emphasizing a dual approach of "left hand innovation drugs, right hand new technology" [1][2]. Core Insights and Arguments - The **2025 strategy** aims to leverage strong liquidity favoring the technology sector while recognizing the innovative drug sector's potential due to market awareness of industry changes [1][2]. - **Cross-border acquisitions** by multinational pharmaceutical companies, such as Kelun-Biotech and Baillie Gifford, indicate a structural advantage for Chinese innovative drugs, driven by a surge in business development (BD) activities [1][4]. - The **global innovative drug industry** is now driven by new technologies, particularly in oncology, with Chinese companies showing competitive strength in areas like Antibody-Drug Conjugates (ADC) and bispecific antibodies [1][6]. - The transition of the Chinese innovative drug market from a "supermarket" model to becoming a global innovation source supplier is crucial, requiring the replacement of certain U.S. biotech products and subsequent BD transactions for funding [1][7][8]. - The development path for Chinese innovative drugs includes three stages: **business development (BD), clinical trials, and commercialization**, with future expansions into small nucleic acids and other new technology fields [1][10][11]. Market Dynamics - The **2025 market performance** of innovative drugs and new technologies has been volatile, with rapid shifts in various sectors, necessitating a clear understanding of underlying logic to avoid missing investment opportunities [2][3]. - The **recent surge** in the innovative drug sector since February 2025 is attributed to significant BD transactions that have shifted market perceptions and created opportunities [5][6]. - Current market adjustments in the innovative drug sector have led to differing opinions on whether this indicates a peak or a temporary pause, highlighting the need for a higher-level understanding of the industry's evolution [7][9]. Challenges and Opportunities - The Chinese innovative drug market faces challenges, including a lack of major industry catalysts and competition for capital from other sectors like AI [13]. - Anticipated catalysts in the fourth quarter, such as data from major conferences and potential spending by multinational companies, are expected to positively influence market expectations [13][14]. Long-term Outlook - Investors are advised to focus on the long-term value of Chinese innovative drugs beyond immediate BD transactions, as successful clinical trials and market entry will enhance valuations over time [9]. - The industry's evolution is projected to take **5 to 10 years**, with a gradual shift towards replacing global biotech functions and achieving a more significant international presence [11][12]. Additional Insights - The relationship between innovative drugs and new medical technologies is characterized by a cyclical interaction, where advancements in one area can stimulate growth in the other [15].

Summary of Key Points from Conference Call Records Industry Overview - The conference call discusses the **innovative drug and pharmaceutical industry** in China, highlighting the recovery of PS and PB ratios in Hong Kong's creative sales companies, although they have not yet reached historical highs, indicating a period of recovery [1][2]. Core Insights and Arguments - **Global Competitiveness of Chinese Innovative Drugs**: China possesses advantages in population, domestic demand, manufacturing, supply chain, and rapidly improving innovation capabilities, which are driving Chinese assets to go global. High-quality early-stage products from China are in significant demand in the U.S. market, with leading companies gradually increasing their performance [1][3]. - **Valuation Trends**: The innovative drug sector's valuation is expected to first recover to previous PS levels and then potentially break new highs as more products are launched and clinical data is disclosed. The number of products is projected to increase, which will enhance company valuations [1][4]. - **Performance of Kangfang Biotech**: Kangfang Biotech's data presented at WCLC showed a p-value of 0.000332 and an HR value of 0.78, indicating significant improvement, especially in brain metastasis patients, which is a rare and meaningful finding [1][5]. - **International Conference Participation**: In 2025, over 70 Chinese studies were showcased at ASCO, with ongoing presentations at international conferences like WCLC and ESMO, indicating China's growing international influence in innovative drug development [1][6][8]. Additional Important Content - **Diverse Treatment Areas**: The innovative drug trend is not limited to oncology but also includes immunology, with upcoming data releases at various international conferences, showcasing significant progress in multiple therapeutic areas [1][8]. - **Future Growth Expectations**: The Chinese innovative drug industry is anticipated to continue significant growth in the coming years, with more new data and products expected as operational logic is refined. The collaboration models are diversifying, enhancing China's global pricing power and influence [1][9]. - **Catalysts for Market Impact**: The second half of 2025 is expected to bring several important catalysts for the Chinese innovative drug market, including potential approvals for new products from leading companies like Heng Rui and developments from companies like Innovent Biologics and BeiGene [1][10][11]. - **Heng Rui Pharmaceutical's Performance**: As a leading company, Heng Rui's performance in the first half of 2025 was outstanding, with a significant increase in the number of products contributing to sales, reflecting its strong position in global transactions [1][12]. - **Innovent Biologics' Growth**: Innovent Biologics reported significant revenue growth of 5.95 billion, a 50.6% year-on-year increase, indicating improved operational efficiency [1][13]. - **Kangfang Biotech's Platform Value**: Kangfang Biotech demonstrated strong performance with a 49.2% growth in product revenue, showcasing its platform's value and potential for new dual and multi-antibody assets [1][14]. - **Bai Jie Shen Zhou's Financial Performance**: Bai Jie Shen Zhou reported a 17.5% quarter-on-quarter revenue increase, exceeding expectations, with new data updates expected in the second half of the year [1][16]. Conclusion - The innovative drug industry in China is on a recovery trajectory, with strong growth potential driven by competitive advantages, increasing product launches, and expanding international presence. The upcoming catalysts and ongoing developments in various companies are expected to further enhance the industry's outlook.